Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02111434

Enrollment

150

Registered

2014-04-11

Start date

2013-07-31

Completion date

2014-04-30

Last updated

2014-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypogonadism

Keywords

visceral adiposity index, triglycerides / hdl cholesterol ratio, testosterone

Brief summary

The study is designed to answer the following questions: 1. What is the levels of visceral adiposity index and Triglycerides/HDL cholesterol ratio in hypogonadism? 2. What is the effect of testosterone replacement on the visceral adiposity index and Triglycerides/HDL cholesterol ratio?

Detailed description

This is a retrospective design, which is performed by investigating the registrations of patients with hypogonadotrophic hypogonadism between the years 2007-2010.

Interventions

DRUGTestosterone

Testosterone 250 mg injection per 3-4 weeks for 6 months

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 26 Years

Healthy volunteers

Yes

Inclusion criteria

* Men * Congenital hypogonadism * Treatment Naive

Exclusion criteria

* Previous history of androgen replacement * Hypertension * Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
time to change of visceral adiposity index with testosteron replacement	baseline and 6 months
time to change of TG/HDL cholesterol ratio with testosteron replacement	baseline and 6 months

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026